MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.medj.2023.12.004

Медицинская библиотека · Med (New York, N.Y.) · 2024

Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.

Mao Long, Shaabani Namir, Zhang Xiaoying, Jin Can, Xu Wanhong, Argent Christopher, Kushnareva Yulia, Powers Colin, Stegman Karen, Liu Jia, Xie Hui, Xu Changxu, Bao Yimei, Xu Lijun, Zhang Yuren, Yang Haigang, Qian Shengdian, Hu Yong, Shao Jianping, Zhang Can, Li Tingting, Li Yi, Liu Na, Lin Zhenhao, Wang Shanbo, Wang Chao, Shen Wei, Lin Yuanlong, Shu Dan, Zhu Zhenhong, Kotoi Olivia, Kerwin Lisa, Han Qing, Chumakova Ludmila, Teijaro John, Royal Mike, Brunswick Mark, Allen Robert, Ji Henry, Lu Hongzhou, Xu Xiao

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Oral antiviral drugs with improved antiviral potency and safety are needed to address current challenges in clinical practice for treatment of COVID-19, including the risks of rebound, drug-drug interactions, and emerging resistance.

METHODS

Olgotrelvir (STI-1558) is designed as a next-generation antiviral targeting the SARS-CoV-2 main protease (Mpro), an essential enzyme for SARS-CoV-2 replication, and human cathepsin L (CTSL), a key enzyme for SARS-CoV-2 entry into host cells.

FINDINGS: Olgotrelvir is a highly bioavailable oral prodrug that is converted in plasma to its active form, AC1115. The dual mechanism of action of olgotrelvir and AC1115 was confirmed by enzyme activity inhibition assays and co-crystal structures of AC1115 with SARS-CoV-2 Mpro and human CTSL. AC1115 displayed antiviral activity by inhibiting replication of all tested SARS-CoV-2 variants in cell culture systems. Olgotrelvir also inhibited viral entry into cells using SARS-CoV-2 Spike-mediated pseudotypes by inhibition of host CTSL. In the K18-hACE2 transgenic mouse model of SARS-CoV-2-mediated disease, olgotrelvir significantly reduced the virus load in the lungs, prevented body weight loss, and reduced cytokine release and lung pathologies. Olgotrelvir demonstrated potent activity against the nirmatrelvir-resistant Mpro E166 mutants. Olgotrelvir showed enhanced oral bioavailability in animal models and in humans with significant plasma exposure without ritonavir. In phase I studies (ClinicalTrials.gov: NCT05364840 and NCT05523739), olgotrelvir demonstrated a favorable safety profile and antiviral activity.

CONCLUSIONS

Olgotrelvir is an oral inhibitor targeting Mpro and CTSL with high antiviral activity and plasma exposure and is a standalone treatment candidate for COVID-19.

FUNDING: Funded by Sorrento Therapeutics.

Для цитирования: Mao Long, Shaabani Namir, Zhang Xiaoying, Jin Can, Xu Wanhong, Argent Christopher, Kushnareva Yulia, Powers Colin, Stegman Karen, Liu Jia, Xie Hui, Xu Changxu, Bao Yimei, Xu Lijun, Zhang Yuren, Yang Haigang, Qian Shengdian, Hu Yong, Shao Jianping, Zhang Can, Li Tingting, Li Yi, Liu Na, Lin Zhenhao, Wang Shanbo, Wang Chao, Shen Wei, Lin Yuanlong, Shu Dan, Zhu Zhenhong, Kotoi Olivia, Kerwin Lisa, Han Qing, Chumakova Ludmila, Teijaro John, Royal Mike, Brunswick Mark, Allen Robert, Ji Henry, Lu Hongzhou, Xu Xiao. Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.. Med (New York, N.Y.). 2024. DOI: 10.1016/j.medj.2023.12.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.